{
  "kind": "framework",
  "value": "biological-pathway-map",
  "collectionKey": "slides:framework:biological-pathway-map:all-document-kinds:all-producers:all-orientations",
  "filters": {
    "documentKinds": [],
    "sourceTypes": [],
    "orientations": []
  },
  "total": 2,
  "page": 1,
  "pageSize": 24,
  "pageCount": 1,
  "rows": [
    {
      "docId": "019de073-7e4e-7689-a01c-e0840dac2b61",
      "docSlug": "97e34d6c4db7d9454440fee3efd43545",
      "documentTitle": "Axcella Health | Results Presentation Deck | 62 slides",
      "authorId": "axcella-health",
      "authorName": "Axcella Therapeutics",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-09-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7761332,
      "pageNumber": 25,
      "slideType": "problem_statement",
      "function": "diagnose_problem",
      "notes": "The slide uses a central biological pathway map (liver/metabolic focus) flanked by comparison tables showing single-target competitors vs AXA1125's multi-target effects.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": "Central diagram showing disease drivers and drug targets",
      "slideHref": "/slides/019de073-7e4e-7689-a01c-e0840dac2b61/25",
      "deckHref": "/decks/019de073-7e4e-7689-a01c-e0840dac2b61",
      "deckAnchorHref": "/decks/019de073-7e4e-7689-a01c-e0840dac2b61#slide-25",
      "loopMatches": [
        {
          "to": 36,
          "from": 6,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "de6af44a-f17d-4c55-adca-ab6e25c41e5d",
          "evidence": "The presentation highlights the need for effective treatment options and the risks associated with disease progression",
          "position": 0,
          "objective": "What is the risk of not treating NASH effectively?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        },
        {
          "to": 30,
          "from": 24,
          "name": "Value Chain Walk",
          "slug": "44-value-chain-walk",
          "bestFor": "Operations improvement, cost reduction, competitive advantage",
          "matchId": "f1102384-67e2-4c89-b8e5-8eb2f1230b26",
          "evidence": "The presentation describes the multi-targeted impact of AXA1125 on NASH disease pathways",
          "position": 1,
          "objective": "How does AXA1125 address the complex disease pathways of NASH?",
          "structure": "Input -> Process Step 1 -> Process Step 2 -> Process Step 3 -> Output -> Value Assessment",
          "confidence": 0.6,
          "description": "Walk through each step of the value chain to identify where value is created or destroyed"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de070-3f4a-73d8-b295-3b15c76ba522",
      "docSlug": "bc1fcb576f82bf5c3541f439604f314c",
      "documentTitle": "Kymera | IPO Presentation Deck | 49 slides",
      "authorId": "kymera",
      "authorName": "Kymera",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investment_bank",
      "sourceTypeLabel": "Investment bank",
      "presentationDate": "2020-08-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 28,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide illustrates a biological pathway and the therapeutic intervention point for a drug candidate.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": "Visual representation of cellular signaling pathways and drug intervention points.",
      "slideHref": "/slides/019de070-3f4a-73d8-b295-3b15c76ba522/28",
      "deckHref": "/decks/019de070-3f4a-73d8-b295-3b15c76ba522",
      "deckAnchorHref": "/decks/019de070-3f4a-73d8-b295-3b15c76ba522#slide-28",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    }
  ]
}